Neurotech International Ltd Total Liabilities

Latest as of June 2026: AU$2.14 Million AUD ≈ $1.51 Million USD

Neurotech International Ltd total liabilities. Based on the latest financial reports, Neurotech International Ltd (NTI) has total liabilities worth AU$2.14 Million AUD (≈ $1.51 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check NTI asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Neurotech International Ltd (2015–2026)

Total liabilities of Neurotech International Ltd from 2015 to 2026. This chart illustrates how Neurotech International Ltd's total liabilities have evolved over time, based on quarterly financial data.

Neurotech International Ltd Competitors by Total Liabilities

The table below lists competitors of Neurotech International Ltd ranked by their total liabilities.

Company Country Total Liabilities
Rathbone Brothers PLC
LSE:RAT
UK GBX3.87 Billion
Birko Birlesik Koyunlulular Mensucat Ticaret ve Sanayi AS
IS:BRKO
Turkey TL76.78 Million
Lyckegard Group AB
ST:LYGRD
Sweden Skr81.25 Million
Mgenplus Co. Ltd.
KQ:032790
Korea ₩22.39 Billion
IXUP Ltd
AU:IXU
Australia AU$2.67 Million
BOXABL Inc.
NASDAQ:BXBL
USA $13.64 Million
Gold Strike Resources Corp.
V:GSR
Canada CA$16.48 Million
Rectitude Holdings Ltd Ordinary Shares
NASDAQ:RECT
USA $17.09 Million

Liability Composition Analysis (2015–2026)

This chart breaks down Neurotech International Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NTI asset base.

Liquidity & Leverage Metrics

Neurotech International Ltd Total Liabilities Ratios Explained

Neurotech International Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 1.29 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 3.50 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.78 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Neurotech International Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Neurotech International Ltd (2015–2026)

The table below shows the annual total liabilities of Neurotech International Ltd from 2015 to 2026.

Year Total Liabilities Change
2026-06-30 AU$2.14 Million
≈ $1.51 Million
+647.62%
2025-06-30 AU$285.74K
≈ $202.18K
-9.20%
2024-06-30 AU$314.70K
≈ $222.67K
-76.63%
2023-06-30 AU$1.35 Million
≈ $952.99K
+127.14%
2022-06-30 AU$592.98K
≈ $419.57K
-48.19%
2021-06-30 AU$1.14 Million
≈ $809.75K
+57.40%
2020-06-30 AU$727.10K
≈ $514.47K
+104.62%
2019-06-30 AU$355.33K
≈ $251.42K
-5.41%
2018-06-30 AU$375.66K
≈ $265.80K
-42.83%
2017-06-30 AU$657.04K
≈ $464.90K
-26.43%
2016-06-30 AU$893.12K
≈ $631.94K
-55.08%
2015-12-31 AU$1.99 Million
≈ $1.41 Million
--

About Neurotech International Ltd

AU:NTI Australia Biotechnology
Market Cap
$18.30 Million
AU$25.86 Million AUD
Market Cap Rank
#25215 Global
#1050 in Australia
Share Price
AU$0.02
Change (1 day)
-5.88%
52-Week Range
AU$0.01 - AU$0.02
All Time High
AU$0.48
About

Neurotech International Limited, a clinical-stage biopharmaceutical development company, focuses on development of solutions for paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy in Australia. The company develops NTI164 to treat autism spectrum disorder, paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, paediatric acute… Read more